A TB Laboratory Protocol for Verifying New Culture Media Batches
Creating a TB lab verification protocol for a new batch of culture media before routine use converts an incoming delivery into a controlled, traceable process. Each lot of Löwenstein–Jensen, Middlebrook or mycobacterial blood agar must be shown to support the intended diagnostic method, remain free from unacceptable contamination and be fit for use under local incubation conditions. The protocol should connect batch records, laboratory testing, acceptance criteria, authorised release and ongoing performance monitoring.
Verification is one part of a wider laboratory quality management system, not a stand-alone bench test. It should address personnel competence, equipment calibration, laboratory safety, documentation, assessment and continual improvement. The four-phase structure and twelve Quality Systems Essentials described by the Global Laboratory Initiative provide a practical framework for adapting the protocol in laboratories with different staffing levels, workloads and budgets.
Define the batch and responsibilities
Begin by recording the manufacturer, product name, catalogue number, formulation, lot or batch number, quantity, expiry date, shipment condition and storage history. State whether the lot is ready to use, requires reconstitution or needs a defined period of conditioning before testing. This prevents results for one formulation from being used to release another and supports an effective recall if a supplier problem emerges.
Assign a batch owner, tester and independent release approver. The tester should confirm competency in inoculum preparation, mycobacterial culture reading and relevant biosafety procedures. The release approver should be able to review source documents, deviations and raw results without relying on verbal assurance. In a small laboratory, one person may hold several roles, but independent review of the final decision should remain possible.
The phase-specific checklists can support mapping these activities to the relevant stage of quality-system development. Major TB laboratory networks in Sydney and Melbourne may operate several culture lines or diagnostic platforms, while regional and rural services may verify media on a smaller scale. NATA accreditation against ISO/IEC 15189 remains a useful reference for documenting competence, traceability and controlled release, regardless of the service model.
Establish acceptance criteria before testing
Make the manufacturer’s instructions for use and lot-specific certificate of analysis the starting authority. Confirm that the delivered product matches the approved specification and was transported and stored within its stated temperature range. Define what constitutes a temperature excursion, how it will be assessed and who may authorise use after an excursion. Do not substitute generic media expectations for product-specific limits.
Set written criteria for packaging integrity, medium appearance, contamination, growth promotion and, where validated, productivity. Physical checks may include leaks, cracks, abnormal colour, drying, uneven medium or damaged agar surfaces. Uninoculated controls should be incubated under the same conditions to reveal contamination, while inoculated reference material demonstrates that the medium can recover the target organisms. Compare colony recovery and time to appearance with the laboratory’s validated baseline or an accepted reference lot.
Criteria must suit the medium. A Löwenstein–Jensen slope, Middlebrook 7H10 or 7H11 plate and mycobacterial blood agar plate have different formulations and performance characteristics. If the method uses 7H9 or another broth, add the relevant growth and contamination checks rather than borrowing solid-media criteria. Specify the reference strain, inoculum preparation, replicate number, incubation temperature, reading schedule and maximum time to positivity. Where a numerical productivity ratio is required, define the calculation and acceptance limit before testing begins.
Perform testing under controlled conditions
Select the number of units and positions within the shipment according to a pre-approved sampling plan, the quantity supplied and the laboratory’s risk assessment. Keep unopened units from the same lot available for confirmatory testing and release. Aseptic technique, calibrated pipettes, documented inoculum viable counts and suitable containment are essential because a contaminated or poorly controlled test can be mistaken for a media failure.
Incubate controls and test media at the manufacturer’s stated temperature, commonly 35–37 °C, using monitored incubators and validated reading intervals. Record the time to detectable growth, colony quantity and morphology, along with any contamination in negative controls. Equipment maintenance, temperature logs, lot identifiers and reagent details should be accessible for review. Where multiple culture methods operate side by side, the quality-system guide helps laboratories connect them through common governance, standard operating procedures and review processes.
Australian procurement adds practical controls. Culture media are commonly ordered through local distributors and may include brands such as Thermo Fisher Scientific/Oxoid, Becton Dickinson or Hardy Diagnostics, so catalogue and pack details should be checked against local supply rather than assumed from an overseas formulary. Customs clearance is handled through Australian Border Force; before any imported shipment arrives, the supplier and laboratory should confirm biosecurity permits, import documentation and quarantine requirements through the relevant Department of Agriculture, Fisheries and Forestry process.
Review evidence and authorise release
The reviewer should compare every result with the pre-approved acceptance criteria. Release requires acceptable identity and storage evidence, satisfactory physical inspection, expected growth promotion, no unacceptable contamination in controls and complete documentation. Deviations must not be converted into pass results through informal judgement. When evidence falls short, place the lot on hold, prevent clinical use and repeat or redesign testing only through an approved investigation.
Record a formal nonconformance for failed or questionable media, including the affected lot, quantity, discovered defect, risk to patient results and actions taken. Assess whether specimens processed on the lot require review, notification or repeat culture, and document the decision through the laboratory’s corrective and preventive action process. Supplier feedback and trend data can support replacement, revised purchase specifications or a change in verification frequency.
Release records should identify who accepted the lot, when it entered use and where it was stored. If a later complaint, contamination event or temperature failure invalidates the original decision, link the investigation to the affected lot and relevant clinical records. This closes the loop between incoming verification, internal quality control, patient safety and continual improvement rather than treating a new batch as an isolated event.
Compare the evidence before release
Verification should combine documentary confidence with laboratory performance evidence. A certificate can establish supplier-controlled characteristics, but it cannot replace local checks of shipment condition, storage, physical integrity and suitability in the laboratory’s workflow. A useful review separates these functions and makes clear which result supports each part of the release decision.
| Area | Manufacturer evidence | Local verification evidence | Release implication |
|---|---|---|---|
| Identity and shelf life | Product specification, lot number and expiry | Delivery record, storage history and remaining shelf life | Hold mismatched or expired stock |
| Physical quality | Declared appearance and pack condition | Inspection for leaks, cracks, colour change, drying or contamination | Reject units outside specification |
| Growth performance | Certificate data and method limits | Growth-promotion or productivity test with authorised reference material | Accept only predefined performance |
| Contamination control | Supplier sterility or quality statements | Incubated uninoculated controls and observations during use | Investigate unexpected growth |
| Documentation and release | Instructions, certificate and supplier traceability | Batch worksheet, raw results, deviation record and authorised sign-off | Complete the record before distribution |
Final approval belongs to the authorised batch approver, not automatically to the person who performed the test. Conditional release should not be used unless the deviation has a documented scientific rationale, a risk assessment and an authorised decision. If the product is acceptable, record the approved lot and distribute it only to controlled storage; if it is unacceptable, quarantine the entire affected quantity and notify the supplier as appropriate.
Make the protocol routine and auditable
Turn the approved form into a controlled laboratory document with a unique version number, effective date, named attachments and a defined review cycle. Keep acceptance criteria visible at the bench, but place the full standard operating procedure, risk assessment and reference information in the quality management system. Train staff before the first batch and retain competency records for inoculum preparation, culture reading and safety.
- Approve the protocol against the current manufacturer’s instructions, applicable accreditation requirements and the laboratory’s quality management system.
- Define lot sampling, test replicates, acceptance limits and authorised decision-makers before media testing begins.
- Maintain a traceable record of supplier, lot, storage, equipment status, test results, deviations and final release approval.
- Quarantine every failed lot and link repeat testing or replacement to a documented nonconformance and corrective action.
- Review supplier performance, contamination findings and media-related corrective actions at regular management meetings.
Australian conditions should be represented without changing manufacturer limits. A central laboratory in Melbourne or Sydney may receive frequent temperature-controlled deliveries, while a remote service in northern Queensland may face heat, humidity or transport delays. Document actual storage and transport conditions, and investigate excursions using product-specific evidence rather than a generic room-temperature assumption.
Begin the next incoming batch by assigning responsibility, opening a lot record and using the GLI Quality Tool to align the local protocol with the relevant phase. Verify every shipment before routine TB culture work begins, and keep the release decision visible, defensible and ready for audit.